Akebia Therapeutics, a US-based firm, develops and distributes novel HIF-based therapeutics for kidney diseases.
Founded in Cambridge, Massachusetts, Akebia Therapeutics is a biopharmaceutical company dedicated to developing and distributing innovative therapeutics based on the biology of hypoxia-inducible factor (HIF) for patients with kidney diseases. The company's core mission is to advance new hope for people with kidney disease by challenging the status quo through research and development. Akebia offers a range of unique products aimed at addressing complications associated with kidney disease, with a strong focus on the renal community.
Notable figures affiliated with Akebia Therapeutics include its experienced leadership team and board members who have extensive backgrounds in biotechnology and pharmaceuticals. The company has attracted significant investment from leading healthcare investors, enabling it to achieve key milestones, including the approval of new oral therapeutics. Akebia's impact is evident in its commitment to improving patient outcomes and its collaborative approach within the renal community, positioning it as a trusted leader in the field of kidney disease therapeutics.
Companies similar to Akebia Therapeutics include Cajal Therapeutics, United Therapeutics, PTC Therapeutics and Astria Therapeutics.
Akebia Therapeutics was founded in 2007.
Akebia Therapeutics' headquarters is located in Cambridge, MA, US.
Akebia Therapeutics' most recent funding round was for $37M (USD) in January 2024.
As of Jan 30, 2024, Akebia Therapeutics has disclosed funding of $442.5M (USD). Undisclosed round amounts are excluded.
Akebia Therapeutics has 205 employees as of Feb 6, 2024.
Astria Therapeutics
astriatx.com
